文献速递白血病

慢性髓性白血病患者无治疗缓解后的晚期分子学复发

Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission.
PubMed 文献 · Blood Adv · 2020-01-01

本研究基于单中心15年注册的128例停用伊马替尼(STIM/A-STIM试验)的慢性髓性白血病患者,中位随访6.5年,7年无治疗缓解率为45.6%;65例分子学复发中9例(14%)为停治疗2年后发生的晚期复发(中位3.6年),2年后晚期复发残余率为18%。微小残留病波动者维持无治疗缓解的概率为65.4%,稳定者为100%(P = .003)。

要点

  • 7年无治疗缓解率估计为45.6%,中位随访6.5年。
  • 65例分子学复发中9例(14%)发生于停治疗2年后,中位3.6年。
  • 停治疗2年后晚期分子学复发残余率为18%。

核心结论

  • 停治疗2年后晚期分子学复发残余率为18%,占所有分子学复发的14%,发生于微小残留病测量波动的患者。
  • 因此对无治疗缓解的慢性髓性白血病患者长期分子学随访仍然必需。

研究设计与样本

  • 单中心注册研究,15年间共128例来自本机构的患者进入Stop Imatinib(STIM;A-STIM)试验。
  • 分子学复发定义为丧失主要分子学反应(BCR-ABL1IS >0.1%)。
  • 首次尝试无治疗缓解时,患者接受酪氨酸激酶抑制剂的中位时间为7.1年,处于BCR-ABL1IS ≤0.01%(MR4)的中位时间为4年。
  • 无治疗缓解患者的中位随访时间为6.5年。
  • A-STIM研究在www.clinicaltrials.gov注册号为#NCT02897245。

主要发现

  • 7年后无治疗缓解率估计为45.6%。
  • 65例发生分子学复发的患者中9例(14%)在无治疗缓解2年后复发,中位3.6年。
  • 停治疗2年后分子学复发残余率估计为18%。
  • 微小残留病波动(至少连续2次BCR-ABL1IS >0.0032%或丧失MR4)的患者维持无治疗缓解的概率为65.4%,而微小残留病稳定者为100%(P = .003)。

关键数值与推荐

  • 分子学复发定义为BCR-ABL1IS >0.1%。
  • 微小残留病波动定义为至少连续2次BCR-ABL1IS >0.0032%或丧失MR4。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment-free remission (TFR) is an opportunity for patients with chronic myeloid leukemia (CML). Reported cumulative incidence curves of molecular recurrence (MRec) arbor a 2-phase shape with mainly early events, but also some late events (late MRec [LMRec]). Having discontinued our first patient in 2004, we have access to a prolonged follow-up, enabling us to characterize these late events. Over 15 years, 128 patients from our institution were registered in the Stop Imatinib (STIM; A Study for Tyrosine Kinase Inhibitors Discontinuation [A-STIM]) trial. MRec was defined by the loss of major molecular response (BCR-ABL1IS >0.1%). At the first TFR attempt, patients had been taking a tyrosine kinase inhibitor for a median of 7.1 years and in BCR-ABL1IS ≤0.01% (MR4) for a median of 4 years. The median follow-up of patients in TFR was 6.5 years. The TFR rate was estimated to be 45.6% after 7 years. For 9/65 (14%) patients experiencing MRec, recurrence occurred after 2 years in TFR (median, 3.6 years). The residual rate of MRec after 2 years was estimated to be 18%. The probability of remaining in TFR was 65.4% for patients having experienced fluctuations of their minimal residual disease (MRD) (at least 2 consecutive measurements BCR-ABL1IS >0.0032% or loss of MR4), whereas it was 100% for those with stable MRD (P = .003). After 2 years in TFR, we observed an 18% residual rate of LMRec. These late events represent 14% of all MRec and occur in patients with fluctuating MRD measurements. A long-term molecular follow-up therefore remains mandatory for CML patients in TFR. The A-STIM study was registered at www.clinicaltrials.gov as #NCT02897245.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Rousselot P, Loiseau C, Delord M, et al. Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission. Blood Adv. 2020. PMID: 32614963. doi:10.1182/bloodadvances.2020001772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。